Latest 10-Q quarterly reports

Leapfrog Acquisition Corporation reports on its financial condition for the quarter ended June 30, 2026, highlighting its status as a SPAC with substantial trust account funds and ongoing efforts to identify a business combination target.

The Cannaisseur Group, Inc. filed its Q2 2026 10-Q, revealing no revenue, a growing deficit, and significant going concern issues, despite a pending acquisition.

BV Financial, Inc. reported its Q2 2026 results, showing a slight decrease in total assets and loans, but maintaining strong capital ratios and improved net interest margin.

Juniata Valley Financial Corp. announced a significant increase in net income for the second quarter of 2026, driven by robust net interest income and improved asset yields.

Universal Token, Inc. reported continued net losses and a going concern warning in its Q2 2026 Form 10-Q, with no revenue generated and significant software development costs.

Table Trac, Inc. announced a significant increase in revenue and net income for the second quarter of 2026, driven by system sales and strong operational performance.

Invech Holdings, Inc. filed its Q2 2026 report, revealing no revenue, a substantial net loss of $202,739 for the six months ended June 30, 2026, and significant concerns about its ability to continue as a going concern.

CareView Communications, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting increased revenues but highlighting a material weakness in internal controls and substantial doubt about its ability to continue as a going concern.

BETA Technologies, Inc. filed its Q2 2026 Form 10-Q, detailing increased revenues in service but also substantial operating losses and R&D investments.

Monopar Therapeutics Inc. files its Q2 2026 Form 10-Q, detailing progress on ALXN1840 for Wilson disease, including near completion of its NDA rolling submission, and advancements in its radiopharmaceutical pipeline.

Nucor Corporation announced robust financial results for the second quarter and first six months of 2026, showcasing substantial increases in net sales and net earnings compared to the prior year.

Neonode Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a decrease in total revenues driven by lower non-recurring engineering income, though license fees saw an increase.

Spruce Biosciences, Inc. filed its Form 10-Q for the period ending June 30, 2026, detailing continued net losses and a focus on advancing its TA-ERT therapy for MPS IIIB, while highlighting the need for substantial additional financing.

Cardiff Lexington Corporation's Q2 2026 Form 10-Q reveals a significant increase in net loss to $2.48 million, driven by declining revenues and rising operating expenses.

Dyadic International reported a net loss of $2.12 million for Q2 2026, with significant concerns remaining about its ability to continue as a going concern.

Aprea Therapeutics reports continued net losses and cash burn, with funding expected to last into Q1 2028, while advancing its APR-1051 clinical program.

QHSLab, Inc. filed its Q2 2026 10-Q, showing increased revenues driven by its Integrated Service Program, but continued operating losses and a going concern warning.

flyExclusive, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a 15.6% increase in revenue to $207.5 million for the first six months, but also highlighting continued net losses and a substantial accumulated deficit.

Avalyn Pharma Inc. details progress in its Phase 2b clinical trial for AP01 and Phase 2 trial for AP02, alongside a robust cash position post-IPO, while acknowledging ongoing development risks.

B&G Foods, Inc. reported a net loss for the period ended July 4, 2026, with a significant decrease in net sales driven by divestitures and base business declines, alongside increased interest expenses.

Century Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued investment in its iPSC cell therapy platform, significant operating losses, and a substantial cash position sufficient into early 2029.

Guerrilla RF, Inc. announced a significant 49% year-over-year revenue increase for the second quarter of fiscal 2026, driven by strong performance in its catalog and infrastructure segments, alongside improved gross margins.

CNS Pharmaceuticals, Inc. filed its Q2 2026 Form 10-Q, detailing financial performance, operational updates, and strategic shifts, including a pivot from glioblastoma multiforme and exploration of out-licensing legacy assets.

LiqTech International Inc. reported a wider net loss for the second quarter of 2026, driven by decreased revenues and increased operating expenses, though a significant capital raise bolstered liquidity.

Xilio Therapeutics files its Q2 2026 Form 10-Q, detailing increased collaboration revenue and ongoing R&D investments, while managing cash runway.

Capstone Holding Corp. has amended its Q3 2025 report to restate prior financial figures related to share counts and net loss per share, while also disclosing material weaknesses in its internal financial reporting controls.

Capstone Holding Corp. has amended its Q2 2025 report to restate weighted average share counts and net loss per share, citing errors in calculation and identifying material weaknesses in internal controls.

Capstone Holding Corp. files an amendment to its Q1 2026 report, restating prior period net loss per share due to an error in calculating weighted average shares, while also disclosing material weaknesses in internal controls and ongoing Nasdaq listing concerns.

Arbutus Biopharma reports a substantial $178.4 million settlement payment from Moderna and positive clinical trial updates for its chronic hepatitis B therapeutic, imdusiran.

Capstone Holding Corp. announced Q2 2026 results, showing increased net sales driven by acquisitions, but continued net losses and ongoing challenges with Nasdaq listing compliance.